Screener
MBX Biosciences, Inc. MBX Total Current Liabilities
Total Current Liabilities at other companies
Other financials
Where this comes from
Reported directly by MBX Biosciences, Inc. in its filing.
Tagged under the XBRL concept us-gaap:LiabilitiesCurrent.
The source filing: MBX Biosciences, Inc.’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 9:03 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-210593
| Line item | March 31, 2026 | December 31, 2025 |
|---|---|---|
| Accounts payable | $6,974 | $2,977 |
| Accrued expenses | 7,415 | 12,346 |
| Operating lease liability, current | 178 | 172 |
| Total current liabilities | 14,567 | 15,495 |
| Share repurchase liability | 1 | 2 |
| Operating lease liability, net of current | 377 | 424 |
| Total liabilities | 14,945 | 15,921 |
| Commitments and contingencies (Note 9) |
Item 1. Financial Statements.
FAQ
- What is MBX Biosciences, Inc.'s total current liabilities?
- MBX Biosciences, Inc. (MBX) reported total current liabilities of $14.57M in Q1 2026.
- How has MBX Biosciences, Inc.'s total current liabilities changed year-over-year?
- MBX Biosciences, Inc.'s total current liabilities increased by 39.0% year-over-year, from $10.48M to $14.57M.
- What is the long-term trend for MBX Biosciences, Inc.'s total current liabilities?
- Over 2 years (2023 to 2025), MBX Biosciences, Inc.'s total current liabilities has grown at a 98.7% compound annual growth rate (CAGR), from $3.93M to $15.5M.
- What does total current liabilities mean?
- The sum of all obligations due within one year — payables, accrued expenses, current debt, deferred revenue, and other short-term liabilities.
Ask your AI about MBX Biosciences, Inc.'s total current liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude